-
1Academic Journal
Authors: S. A. Shalnova, V. A. Metelskaya, V. A. Kutsenko, E. B. Yarovaya, A. V. Kapustina, G. A. Muromtseva, G. E. Svinin, Yu. A. Balanova, A. E. Imaeva, S. E. Evstifeeva, V. G. Vilkov, O. L. Barbarash, O. A. Belova, Yu. I. Grinshtein, A. Yu. Efanov, O. N. Kalachikova, N. V. Kulakova, O. P. Rotar, I. A. Trubacheva, D. V. Duplyakov, R. A. Libis, I. A. Viktorova, A. N. Redko, S. S. Yakushin, S. A. Boytsov, E. V. Shlyakhto, O. M. Drapkina, С. А. Шальнова, В. А. Метельская, В. А. Куценко, Е. Б. Яровая, А. В. Капустина, Г. А. Муромцева, Г. Е. Свинин, Ю. А. Баланова, А. Э. Имаева, С. Е. Евстифеева, В. Г. Вилков, О. Л. Барбараш, О. А. Белова, Ю. И. Гринштейн, А. Ю. Ефанов, О. Н. Калачикова, Н. В. Кулакова, О. П. Ротарь, И. А. Трубачева, Д. В. Дупляков, Р. А. Либис, И. А. Викторова, А. Н. Редько, С. С. Якушин, С. А. Бойцов, Е. В. Шляхто, О. М. Драпкина
Contributors: The ESSE-RF study was carried out within the framework of the state task for 2012-2014 of the Federal State Budgetary Institution «Russian Cardiology Research and Production Complex» of the Ministry of Health and Social Development of Russia, the Federal State Budgetary Institution «State Research Center for Preventive Medicine» of the Ministry of Health and Social Development of Russia and the Federal State Budgetary Institution «Center for Heart, Blood and Endocrinology named after V.A. Almazov» of the Ministry of Health and Social Development of Russia in part 2 under section I: «Epidemiological studies and modeling of the risk of cardiovascular diseases and their complications». The prospective part of the study was carried out as part of the state task for 2020-2022. No. АААА-А20-120013090086-0 to the Federal State Budgetary Institution National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of the Russian Federation, Moscow «Risk factors for chronic NCDs, their significance for predicting the health of the population of various age groups in some regions of the Russian Federation. Evaluation of the impact on morbidity and mortality (population study)»., Исследование ЭССЕ-РФ выполнено в рамках государственного задания на 2012-2014 гг ФГБУ «Российский кардиологический научно-производственный комплекс» Минздравсоцразвития России, ФГБУ «Государственный научно-исследовательский центр профилактической медицины» Минздравсоцразвития России и ФГБУ «Центр сердца, крови и эндокринологии имени В.А. Алмазова» Минздравсоцразвития России в части 2 по разделу I: «Эпидемиологические исследования и моделирование риска сердечно-сосудистых заболеваний и их осложнений». Проспективная часть исследования выполнена в рамках государственного задания на 2020-2022 гг. № АААА-А20-120013090086-0 для ФГБУ «Национальный медицинский исследовательский центр терапии и профилактической медицины» Минздрава России, Москва «Факторы риска ХНИЗ, их значение для прогноза здоровья населения различных возрастных групп в некоторых регионах РФ. Оценка влияния на заболеваемость и смертность (популяционное исследование)».
Source: Rational Pharmacotherapy in Cardiology; Vol 18, No 4 (2022); 366-375 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 4 (2022); 366-375 ; 2225-3653 ; 1819-6446
Subject Terms: исследование ЭССЕ-РФ, non-high-density lipoprotein cholesterol, cardiovascular risk, ESSE-RF Study, холестерин, не входящий в состав липопротеинов высокой плотности, сердечно-сосудистый риск
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/2784/2333; https://www.rpcardio.com/jour/article/view/2784/2350; Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 1979;90(1):85-91. DOI:10.7326/0003-4819-90-1-85.; Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. DOI:10.1093/eurheartj/ehx144.; Shestov DB, Deev AD, Klimov AN, et al. Increased risk of coronary heart disease death in men with low total and low-density lipoprotein cholesterol in the Russian Lipid Research Clinics Prevalence Follow-up Study. Circulation. 1993;88(3):846-53. DOI:10.1161/01.cir.88.3.846.; 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455.; Feldman HA, Zuber K, Davis J. Dyslipidemia How Low Should We Go? A Review of Current Lipid Guidelines. Physician Assist Clin. 2017;2(4):633-50. DOI:10.1016/j.cpha.2017.06.004.; Dembowski E, Davidson MH. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev. 2009;29(1):2-12. DOI:10.1097/HCR.0b013e318192754e.; Stroes E. Statins and LDL-cholesterol lowering: an overview. Curr Med Res Opin. 2005;21 Suppl 6:S9-16. DOI:10.1185/030079905X59102.; Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis. 2018;277:483-92. DOI:10.1016/j.atherosclerosis.2018.06.859.; Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 1998;81(4A):26B-31B. DOI:10.1016/s0002-9149(98)00034-4.; Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97. DOI:10.1001/jama.285.19.2486.; Wang S, Tu J, Pan Y. Threshold Effects in the Relationship Between Serum Non-High-Density Lipoprotein Cholesterol and Metabolic Syndrome. Diabetes Metab Syndr Obes. 2019;12:2501-06. DOI:10.2147/DMSO.S232343.; Enkhmaa B, Prakash N, Berglund L. Non-HDL-C levels and residual cardiovascular risk: Do population-specific precision approaches offer any advantages? Atherosclerosis. 2018;274:230-1. DOI:10.1016/j.atherosclerosis.2018.05.010.; Expert Dyslipidemia Panel, Grundy SM. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7(6):561-5. DOI:10.1016/j.jacl.2013.10.001.; de Oliveira Alvim R, Mourao-Junior CA, Magalhaes GL, et al. Non-HDL cholesterol is a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population. Clinics (Sao Paulo). 2017;72(2):106-10. DOI:10.6061/clinics/2017(02)07.; Grundy SM, Stone NJ, Bailey AL, et al. 2018 HA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-209. DOI:10.1016/j.jacc.2018.11.002.; Aggarwal DJ, Kathariya MG, Verma DPK. LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker. Indian Heart J. 2021;73(5):544-8. DOI:10.1016/j.ihj.2021.07.013.; Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol. 2009;55(1):42-4. DOI:10.1016/j.jacc.2009.07.056.; Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161(11):1413-9. DOI:10.1001/arch-inte.161.11.1413.; Bittner V, Hardison R, Kelsey SF, et al.; Bypass Angioplasty Revascularization Investigation. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106(20):2537-42. DOI:10.1161/01.cir.0000038496.57570.06.; Kathariya G, Aggarwal J, Garg S, et al. Is evaluation of non- HDL- C better than calculated LDL-C in CAD patients? MMIMSR experience. Indian Heart J. 2020;72(3):189-91. DOI:10.1016/j.ihj.2020.05.008.; Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis. 2019;18(1):134. DOI:10.1186/s12944-019-1080-x.; Puri R, Mehta V, Lyenger S., et al. Non-HDL Cholesterol and Atherosclerotic Cardiovascular Disease. J Assoc Physicians India. 2020;68(11[Special]):54-58.; Orringer CE. Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment. Clin Lipidology. 2013;8(1):69-79. DOI:10.2217/clp.12.89.; Maki KC, Bays HE, Dicklin MR. Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. J Clin Lipidol. 2012;6(5):413-26. DOI:10.1016/j.jacl.2012.04.003.; Visseren FLJ, Mach F, Smulders YM, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab484.; Pencina KM, Thanassoulis G, Wilkins JT, et al. Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention. J Am Coll Cardiol. 2019;74(1):70-9. DOI:10.1016/j.jacc.2019.04.047.; Feeman WE. Concerns about the use of non-high-density lipoprotein cholesterol as a lipid predictor. Eur Med J. 2017;2(2):57-64.; Brunner FJ, Waldeyer C, Ojeda F, et al. on behalf of the Multinational Cardiovascular Risk Consortium. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet. 2019;394(10215):2173-83. DOI:10.1016/S0140-6736(19)32519-X.; Zhang P, Su Q, Ye X, et al. Trends in LDL-C and Non-HDL-C Levels with Age. Aging Dis. 2020;11(5): 1046-1057. DOI:10.14336/AD.2019.1025.; https://www.rpcardio.com/jour/article/view/2784
-
2Academic Journal
Authors: A. N. Sumin, G. V. Artamonova, O. I. Raykh, E. V. Indukaeva
Source: Рациональная фармакотерапия в кардиологии, Vol 11, Iss 3, Pp 261-266 (2015)
Subject Terms: 2. Zero hunger, esse-rf study, тип личности Д, факторы риска, RM1-950, type d personality, cardiovascular diseases, исследование ЭССЕ-РФ, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, RC666-701, risk factors, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology, сердечно-сосудистые заболевания
Access URL: http://www.rpcardio.com/jour/article/download/88/95
https://doaj.org/article/5ae000cecf894e47b8a39e240d34b9a8
https://doaj.org/article/3eca03c27d6843df8363458a3b6d10f0
https://www.rpcardio.com/jour/article/view/88
https://www.rpcardio.com/jour/article/download/88/95
https://core.ac.uk/display/87816891 -
3Academic Journal
Authors: S. E. Evstifeeva, S. A. Shalnova, A. D. Deev, T. M. Gatagonova, A. Yu. Efanov, Yu. V. Zhernakova, V. A. Il'in, A. O. Konradi, V. A. Metelskaya, E. V. Oschchepkova, S. V. Romanchuk, O. P. Rotar, I. A. Trubacheva, E. V. Shlyakhto, S. A. Boytsov
Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 6, Pp 597-605 (2015)
Subject Terms: исследование ЭССЕ-РФ, распространенность, ассоциации, вялотекущее воспаление, высокочувствительный С-рекактивный белок, факторы риска, заболевания, Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701
File Description: electronic resource
-
4Academic Journal
Authors: A.O. Konradi, V. A. Il'in, T. M. Gatagonova, V A Metelskaya, Evgeny Shlyakhto, E. V. Oschchepkova, Svetlana V. Romanchuk, S. A. Shalnova, O. P. Rotar, Sergey Boytsov, Yu V Zhernakova, I. A. Trubacheva, A. D. Deev, S. E. Evstifeeva, A. Yu. Efanov
Source: Рациональная фармакотерапия в кардиологии, Vol 10, Iss 6, Pp 597-605 (2015)
Subject Terms: 2. Zero hunger, 4. Education, вялотекущее воспаление, распространенность, высокочувствительный С-рекактивный белок, заболевания, факторы риска, RM1-950, ассоциации, исследование ЭССЕ-РФ, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, RC666-701, Diseases of the circulatory (Cardiovascular) system, Therapeutics. Pharmacology
Access URL: http://www.rpcardio.com/jour/article/download/278/292
https://doaj.org/article/1b5b067dac0847b99e4dcaf887fdb025
https://doaj.org/article/9b7147a4e3ae4317ac8081568171105c
https://www.rpcardio.com/jour/article/download/278/292
https://doaj.org/article/1b5b067dac0847b99e4dcaf887fdb025
https://core.ac.uk/display/87816499
https://www.rpcardio.com/jour/article/view/278 -
5Academic Journal
Authors: S. Evstifeeva E., S. Shalnova A., A. Deev D., V. Metelskaya A., G. Artamonova V., O. Belova A., J. Zhernakova V., A. Efanov Yu., A. Konradi O., N. Kulakova V., O. Rotar P., G. Tolparov V., I. Trubacheva A., A. Shabunova A., S. Boytsov A., С. Евстифеева Е, С. Шальнова А., А. Деев Д., В. Метельская А., Г. Артамонова В., О. Белова А., А. Ефанов Ю., Ю. Жернакова В., А. Конради О., Н. Кулакова В., О. Ротарь П., Г. Толпаров В., И. Трубачева А., А. Шабунова А., С. Бойцов А.
Source: Rational Pharmacotherapy in Cardiology; Vol 12, No 2 (2016); 129-137 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 2 (2016); 129-137 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-2
Subject Terms: the ESSE-RF study, prevalence, associations, level of depression, high-sensitivity CRP, the risk factors, diseases, исследование ЭССЕ-РФ, распространенность, ассоциации, уровень депрессии, высокочувствительный СРБ, факторы риска, заболевания
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/1227/1248; Results from the Global Burden of Disease Study 2010 (GBD 2010). Available at: http://www.who.int/healthinfo/global_burden_disease/gbd/en/. Checked by 07.04.2016; Baune BT. Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention? Curr Opin Psychiatry 2015;28(2):148-54.; Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosc Biobehav Rev 2012;36(2):764-85.; Bakunina N, Pariante CM, Zunszain PA. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology 2015. doi:10.1111/imm.12443.; Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.; Kreisel T, Frank MG, Licht T, et al. Dynamic microglial alterations underlie stress-induced depressivelike behavior and suppressed neurogenesis. Molecular Psychiatry 2014;19(6):699-709.; Copeland WE, Shanahan l, Worthman C, et.al. Comulative Depression Episodes Predict Later C-reactive Protein Levels: A Prospective Analysis Biol Psychiatry 2012;71:15-21.; Setiawan E, Wilson AA, Mizrahi R, et al. Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes. JAMA Psychiatry 2015; 72(3):268-75.; Kreisel T, Frank MG, Licht T, et al. Dynamic microglial alterations underlie stress-induced depressivelike behavior and suppressed neurogenesis. Mol Psychiatry 2014; 19(6): 699-709.; Scientific and Organizing Committee of the Russian Federation essay. The epidemiology of cardiovascular disease in different regions of Russia (ESSE-RF). Rationale and design of the study. Profilakticheskaya Meditsina 2013;6:25-34. In Russian (Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайн исследований. Профилактическая медицина 2013;6:25-34).; Andryushchenko AV, Drobizhev MD, Dobrovol'skiy AV. Sravnitel'naya ocenka shkal CES-D i HADS v diagnostike depressiy obshemedicinskoy praktiki. Zhurnal nevrologii i psikhiatrii im. Korsakova ;5:11-8. In Russian (Андрюшенко А.В., Дробижев М.Ю., Добровольский А.В. Сравнительная оценка шкал CES-D, BDI и HADS(d) в диагностике депрессий в общемедицинской практике. Журнал неврологии и психиатрии 2003;5:11-7).; Pearson T, Mensah G, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.; Howren MB, Lamkin DM, Suls J. Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis. Psychosomatic 2009;71(2):171-86.; Elovainio M, Aalto AM, Kivimäki M, et al. Depression and C-reactive protein: population-based health 2000 study. Psychosomatic 2009;71(4):423-30.; Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third NationalHealth and Nutrition Examination Survey. Archives of Internal Medicine 2004;164(9):1010-14.; Hsu-Ko K, Chung-Jen Y, Chia-Hsuin C, et al. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005;4(6):371-80.; Haapakoski R., Mathieu J., Ebmeier KP. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behavior and Immunity 2015; 49: 206-15.; Ma Y, Chiriboga DE, Sherry L, et.al. Association between Depression and C-Reactive Protein. Cardiol Res Pract 2010;2011:286509.; Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology 2006;27(1):24-31.; Dinan T. Inflammatory markers in depression. Current Opinion in Psychiatry 2009; 22(1):32-6.; Miller AH, Maletic V, Raison C. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biological Psychiatry 2009;65(9):732-41.; Duivis HE, Vogelzangs N, Kupper N, et al. Differential association of somatic and cognitive symptoms of depression and anxiety with inflammation: Findings from the Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 2013;38:1573-85.; Shal'nova SA, Evstifeeva SE, Deev AD, et.al. The prevalence of anxiety and depression in different regions of the Russian Federation and its association with sociodemographic factors (according to the data of the ESSE-RF study). Terapevticheskij arkhiv 2014;12:52-9. In Russian (Шальнова С.А., Евстифеева С.Е., Деев А.Д. и др. Распространенность тревоги и депрессии в различных регионах Российской Федерации и ее ассоциации с социально-демографическими факторами (по данным исследования ЭССЕ-РФ). Терапевтический архив 2014;12:52-9).; Evstifeeva SE, Shal'nova SA, Deev AD, et.al. The prevalence of elevated levels of C-reactive protein and its association with traditional risk factors and morbidity among residents of the Russian Federation (according to the ESSE-RF study). Rational Pharmacotherapy in Cardiology 2014;10(6):597-605. In Russian (Евстифеева С.Е., Шальнова С.А., Деев А.Д. и др. Распространенность повышенного уровня С-реактивного белка и его ассоциации с традиционными факторами риска и заболеваемостью у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Рациональная Фармакотерапия в Кардиологии 2014;10(6):597-605.; Academic highlights of the primary care companion. Translating evidence of depression and physical symptoms into effective clinical practice. J Clin Psychiatry 2007;9(4):295-302.; Zeltyn AE, Fofanova YuS, LisitsinaTA, et.al. Chronic stress and depression in patients with rheumatoid arthritis Hronicheskij stress i depressija u bol'nyh revmatoidnym artritom. Social'naja i klinicheskaja psihiatrija 2009;19:2:69-75. In Russian (Зелтынь А.Е., Фофанова Ю.С., Лисицына Т.А. и др. Хронический стресс и депрессия у больных ревматоидным артритом. Социальная и клиническая психиатрия 2009;19:2:69-75).; Empana JP, Sykes DH, Luc G, et.al. Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005;111:2299-305.; https://www.rpcardio.com/jour/article/view/1227
-
6Academic Journal
Authors: S. Evstifeeva E., S. Shalnova A., A. Deev D., T. Gatagonova M., A. Efanov Yu., Yu. Zhernakova V., V. Il'in A., A. Konradi O., V. Metelskaya A., E. Oschchepkova V., S. Romanchuk V., O. Rotar P., I. Trubacheva A., E. Shlyakhto V., S. Boytsov A., С. Евстифеева Е., С. Шальнова А., А. Деев Д., Т. Гатагонова М., А. Ефанов Ю., Ю. Жернакова В., В. Ильин А., А. Конради О., В. Метельская А., Е. Ощепкова В., С. Романчук В., О. Ротарь П., И. Трубачева А., Е. Шляхто В., С. Бойцов А.
Source: Rational Pharmacotherapy in Cardiology; Vol 10, No 6 (2014); 597-605 ; Рациональная Фармакотерапия в Кардиологии; Vol 10, No 6 (2014); 597-605 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2014-10-6
Subject Terms: исследование ЭССЕ-РФ, распространенность, ассоциации, вялотекущее воспаление, высокочувствительный С-рекактивный белок, факторы риска, заболевания
File Description: application/pdf
Relation: https://www.rpcardio.com/jour/article/view/278/292; Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J Am Coll Cardiol 2010;55:1169-77.; Danesh J, Whincup P, Walker M, et al. Low grade infl ammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204.; Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.; Pearson T, Mensah G, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.; Scientific and Organizing Committee of the Russian Federation essay. The epidemiology of cardiovascular disease in different regions of Russia (ESSE-RF). Rationale and design of the study. Profilakticheskaya Meditsina 2013; 6: 25-34. Russian (Научно-организационный комитет проекта ЭССЕ-РФ. Эпидемиология сердечно-сосудистых заболеваний в различных регионах России (ЭССЕ-РФ). Обоснование и дизайин исследований. Профилактическая Медицина 2013;6:25-34).; Ridker PM. C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease. Clinical Chemistry 2009;55:2 209-15.; Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005;352:1611-3.; Wang Z, Hoy WE. Population Distribution Of High Sensitivity C-Reactive Protein Values in Aboriginal ustralians: A Comparison With Other Populations. Clin Biochem 2006;39(3):277-81.; Hutchinson WL, Koenig W, Frohlich M, et al. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000;46:934-8.; Albert MA Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003;108:161-5.; Ford E, Giles W, Myers G, et al Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999–2000. Clin Chem 2003;49:1353-7.; Nasermoaddel A, Sekine M. Kagamimori S. Gender Differences in Associations of C-Reactive Protein With Atherosclerotic Risk Factors and Psychosocial haracteristics in Japanese Civil Servants. Psychosomatic Medicine 2006;68:1:58-63.; Marques-Vidal P, Mazoyer E, Bongard V, et al. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002;25:1371-7.; Imhof A, Frohlich M, Loewel H, et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49:669-72.; Winston H, Koenig W, Frohlich M. Immunoradiometric Assay of Circulating C-Reactive Protein: Agerelated Values in the Adult General Population. Clinical Chemistry 2000;46:7 934-8.; Loucks EB, Sullivan LM, Hayes LJ, et al. Association of Educational Level with Inflammatory Markers in the Framingham Offspring Study. Am J Epidemiol 2006:163:7:622-8.; Nazmi A, Victora C. Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health 2007;7:212.; Dhingra R, Gona P, Nam BH, et al. С-Reactive Protein, Inflammatory Conditions and Cardiovascular Disease Risk. Am J Med 2007;120:12: 1054-62.; Loucks EB, Sullivan L, Hayes L, et al. Association of Educational Level with Inflammatory Markers in the Framingham Offspring Study. Am J Epidemiol 2006;163:7:622-8.; Zhukova VA, Shalnova SA, Metelskaya VA, et al. The results of population-based study "Stress, aging and health in Russia". Kremlevskaya meditsina. Klinicheskiy Vestnik 2012: 1: 136-8. Russian (Жукова В.А., Шальнова С.А., Метельская В.А., и др. Результаты популяционного исследования «Стресс, старение и здоровье в России». Кремлевская медицина. Клинический Вестник 2012:1;136-8).; Wannamethee S, Lowe G, Shaper A, et al. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005;26(17):1765-73.; Averina M, Nilssen O, Arkhipovsky V, et al. C-reactive protein and alcohol consumption: Is there a Ushaped association? Results from a population-based study in Russia The Arkhangelsk study. Atherosclerosis 2006;188:309-15.; Han T, Sattar N, Williams K, et al. Prospective Study of C-Reactive Protein in Relation to the Development of Diabetes and Metabolic Syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25:2016-21.; Laaksonen D, Niskanen L, Nyyssonen K, et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47:1403-10.; Ford E. Body Mass Index, Diabetes, and C-Reactive Protein Among U.S. Adults. Diabetes Care 1999;22:1971-7.; Grundy S. Obesity, metabolite syndrome and coronary atherosclerosis. Circulation 2002;105:26-98.; Indulekha K, Surendar J, Mohan V. C-Reactive Protein, Tumor Necrosis Factor-α, Interleukin-6, and Vascular Cell Adhesion Molecule-1 Levels in Asian Indians with Metabolic Syndrome and Insulin Resistance (CURES-105). J Diabetes Sci Technol 2011;5:4:982-8.; Morrow D, Lemos J. Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation 2007;115:949-52.; Sesso HD, Burning GE, Rafai N, et al. C-reactive protein and the risk of development hypertension. JAMA 2003;290:2945-51.; Bautista LE, Vera LM, Arenas IA, et al. Independent association between inflammatory markers (Creactive protein, interleukin 6 and TNF-alpha) and essential hypertension. J Hum Hypertens 2005; 19 (2): 149-54.; Cifcova R, Frohlich J, Skodova Z, et al. C-reactive protein and the risk of developing hypertension. A population study. J Hypertens 2004;22:262.; Zacho J, Tybjærg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. October 30, 2008;359:1897-908.; Ridker P, Charles H, Hennekens M, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.; Bekbosynova MS, Nikitina TY, Golitsyn SP, et al. The level of C-reactive protein and the incidence of autoantibodies against β1-adrenoceptor in patients with supraventricular tachyarrhythmias. Kardiologiya 2006; 7: 55-61. Russian (Бекбосынова М.С., Никитина Т.Я., Голицин С.П. и др. Уровень С-реактивного белка и частота выявления аутоантител к β1-адренорецепторам у больных с наджелудочковыми тахиаритмиями. Кардиология 2006;7:55-61).; de Torres JP, Cordoba-Lanus E, López-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006;27:5:902-7.; https://www.rpcardio.com/jour/article/view/278
-
7Academic Journal
Authors: N. S. Karamnova, A. I. Rytova, O. B. Shvabskaya, S. A. Shalnova, S. A. Maksimov, Yu. A. Balanova, S. E. Evstifeeva, A. E. Imaeva, A. V. Kapustina, G. A. Muromtseva, O. M. Drapkina
Source: Кардиоваскулярная терапия и профилактика, Vol 20, Iss 4 (2021)
Subject Terms: характер питания, пищевые привычки, потребление алкогольных напитков, алкоголь, исследование эссе-рф, Diseases of the circulatory (Cardiovascular) system, RC666-701, socio, demo
Availability: https://doi.org/10.15829/1728-8800-2021-2883
-
8Academic Journal
Authors: Евстифеева, Светлана, Шальнова, Светлана, Деев, Александр, Гатагонова, Тамара, Ефанов, Алексей, Жернакова, Юлия, Ильин, Владимир, Конради, Александра, Метельская, Виктория, Ощепкова, Елена, Романчук, Светлана, Ротарь, Оксана, Трубачева, Ирина, Шляхто, Евгений, Бойцов, Сергей, Баланова, Юлия, Гомыранова, Наталия, Капустина, Анна, Концевая, Анна, Литинская, Ольга, Мамедов, Мехман, Муромцева, Галина, Оганов, Рафаэль, Суворова, Евгения, Худяков, Михаил, Баранова, Елена, Касимов, Риза, Шабунова, Александра, Калашников, Константин, Калачикова, Ольга, Кондакова, Н., Попов, Андрей, Устинова, К., Белова, Ольга, Назарова, Ольга, Шутемова, Е., Кавешников, Владимир, Карпов, Ростислав, Серебрякова, Виктория, Медведева, Ирина, Сторожок, Марина, Шава, Владимир, Шалаев, Сергей, Гутнова, Светлана, Толпаров, Георгий
Subject Terms: ИССЛЕДОВАНИЕ ЭССЕ-РФ, РАСПРОСТРАНЕННОСТЬ, АССОЦИАЦИИ, ВЯЛОТЕКУЩЕЕ ВОСПАЛЕНИЕ, ВЫСОКОЧУВСТВИТЕЛЬНЫЙ С-РЕКАКТИВНЫЙ БЕЛОК, ФАКТОРЫ РИСКА, ЗАБОЛЕВАНИЯ
File Description: text/html
-
9Academic Journal
Source: Рациональная фармакотерапия в кардиологии.
Subject Terms: 2. Zero hunger, ТИП ЛИЧНОСТИ Д, ФАКТОРЫ РИСКА, СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ, ИССЛЕДОВАНИЕ ЭССЕ-РФ, 3. Good health
File Description: text/html
-
10Academic Journal
Source: Рациональная фармакотерапия в кардиологии.
Subject Terms: ИССЛЕДОВАНИЕ ЭССЕ-РФ, РАСПРОСТРАНЕННОСТЬ, АССОЦИАЦИИ, ВЯЛОТЕКУЩЕЕ ВОСПАЛЕНИЕ, ВЫСОКОЧУВСТВИТЕЛЬНЫЙ С-РЕКАКТИВНЫЙ БЕЛОК, ФАКТОРЫ РИСКА, ЗАБОЛЕВАНИЯ, 3. Good health
File Description: text/html
